Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-07-30
Item 5.02
The Board appointed Colleen Martin-Garcia as the Company's principal accounting officer on July 29, 2026. While the disclosure also mentions Kevin Kraus's cessation of this role, the principal action disclosed is Ms. Martin-Garcia's appointment to a key officer position, supported by her compensation package (base salary $360,000, 50% target bonus, and 600,000 RSUs vesting over three years). This is a material executive appointment affecting the registrant's financial reporting structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
Hege Sollie-Zetlmayer was appointed to PTC Therapeutics' Board of Directors effective July 28, 2026, filling a board vacancy. The appointment includes compensatory arrangements consisting of a base retainer of $50,000 and equity grants of stock options and RSUs.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-30
The 6-K discloses the appointment of Mr. Zhanchang Xin as Chairman of the Board and Ms. Hong Li as Co-Chief Executive Officer, both effective July 30, 2026. While the filing also mentions the resignation of Mr. Chen Xin (the prior Chairman and Co-CEO), the principal disclosed action is the appointment of new leadership to these senior executive roles. The appointment of a new Chairman and Co-CEO represents a material change in corporate governance and leadership structure that would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-30
Item 5.02
Peter Pitts was appointed as Executive Chairman and Chief Strategic Regulatory Officer effective July 24, 2026, with a 900,000-share stock option grant. The appointment represents a significant leadership transition, with Pitts, a former FDA Associate Commissioner, assuming operational control over daily strategic operations and clinical-regulatory pathways for the company's Phase 3b trial. Jacob Frenkel resigned as Chairman and transitioned to Senior Advisor, and Ibrahim Dagher departed as Chief Medical Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-30
Item 5.02
Robert E. Knowling, Jr. was appointed as Chief Executive Officer effective July 29, 2026, succeeding James J. Rhyu. Steven B. Fink was appointed as Chair of the Board, and Brian Shepherd was appointed to the Board, representing a material executive succession and leadership restructuring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The filing discloses the appointment of John R. Rutherford as an independent director of Flowco Holdings Inc., effective July 29, 2026, to fill a Board vacancy. While the disclosure includes compensatory details (RSU grant of 2,629 units valued at $53,425), the principal action is the appointment itself. The appointment of a new independent director to the Board and assignment to two Board committees is a governance event material to investors assessing board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 8.01
The filing discloses the appointment of Jennifer O. Kozak to the position of Senior Vice President, Chief Human Resources Officer, effective September 9, 2026, and her addition to the Executive Leadership Team. This is a clear executive appointment of a named officer to a senior leadership role, making it material to investors assessing the company's leadership and organizational capability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-07-30
Item 5.02
Erica McLaughlin was elected President and Chief Executive Officer effective October 1, 2026, and elected to the Board of Directors. The appointment follows the retirement of Sean Keohane as CEO and resignation as Director effective September 30, 2026, completing a planned succession transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The board of directors elected Tobias B. Moss as a member of the board effective July 28, 2026, to replace departing director Belvin Williamson, Jr. The principal disclosed action is the appointment of a director to the board, making this an exec_appointment event. Board composition changes are material to investors' assessment of governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-30
Item 5.02
Adam Benson and Soumya Das were appointed to the Board of Directors effective July 28, 2026, with Das also becoming Board chairperson. Benson was identified as an independent director and audit committee financial expert who will chair multiple committees, reflecting material governance changes coinciding with the company's direct listing on Nasdaq.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The filing discloses the appointment of Kathleen Oates as Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer) effective immediately on July 27, 2026. While the disclosure also references the concurrent departure of Nina Baryski, the principal action disclosed is Oates taking on these critical financial officer roles. The appointment of a principal financial officer is material to investors as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-30
EX-99.1
The press release announces that Nir Brenmiller has assumed the role of Chief Executive Officer of Brenmiller Energy effective upon shareholder approval at the July 29, 2026 Annual and Special General Meeting. This is a clear executive appointment of a named officer to a principal leadership position. While the release also mentions shareholder approval of a name change and strategic initiatives (BrenX), the primary disclosed action is the CEO appointment, which is material to investors assessing company leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The filing discloses the appointment of Sanjay Shah as a Class III director on July 28, 2026, with a detailed biography highlighting his extensive executive experience at major companies (Starbucks, Tesla, Amazon, Beyond Meat). While the disclosure also includes compensatory details (stock option grant of 375,000 shares), the principal disclosed action is the director appointment itself, making exec_appointment the most salient classification. The appointment of a seasoned executive to the board is material to investors assessing governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
Christopher D. Adams was appointed as Executive Chair of the Board effective July 29, 2026, transitioning from a non-employee director role to an executive officer position with a $750,000 annual base salary and five-year initial term.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
Jed Dolson, the Company's President and Chief Operating Officer, was promoted to Co-Chief Executive Officer effective October 15, 2026, representing a material elevation in responsibility and authority within the organization as part of the Board's long-term succession planning.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
Chris Aaker was appointed Chief Technology Officer effective August 1, 2026, representing a promotion from Senior Vice President of Engineering as part of a planned technology leadership succession. David Wang transitioned from CTO to Senior Vice President of Platform and Architecture, remaining with the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-30
Item 5.02
The filing discloses two executive appointments: (1) Brijesh Krishnaswamy as Chief Operating Officer, effective August 24, 2026 (part-time) and September 30, 2026 (full-time), with a base salary of $550,000, bonus target of 60%, and $1.2M in equity awards; and (2) Ethan Brown's appointment to the board as a Class III director on July 28, 2026. The COO appointment is the more material event, involving a C-suite officer with significant compensation and equity incentives. While the section also mentions John Boken ceasing to perform interim COO duties, the principal disclosed action is the appointment of Krishnaswamy to the COO role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-30
Item 5.02
DXC Technology appointed Paul J. Taylor as President, DXC effective August 10, 2026, with a $1 million base salary, 200% bonus target, 900% equity target, and a $3.75 million inducement award. The company also appointed Dan Gray as President of Global Infrastructure Services. Chris Drumgoole departed as President, Global Infrastructure Services to pursue an external role while continuing in an advisory capacity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The filing discloses the appointment of Rob O'Hare as a director and Audit Committee member effective July 30, 2026. While the disclosure includes compensatory details (RSU grant of $480,000 and $40,000 annual retainer), the principal action is the appointment itself. The appointment of a qualified director with extensive public company CFO experience and fintech expertise to the board and audit committee is material to investors' assessment of governance and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The filing discloses the election of two new directors, Frederick J. Crawford and Paul J. Smith, to Humana's Board effective July 28, 2026, expanding the board from eleven to thirteen members. Both individuals are described as independent directors and will receive RSU grants under the company's director compensation program. This is a clear executive appointment event, material to investors as board composition affects governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Peter Carter, age 63 and currently President of Delta Air Lines, was elected to Xcel Energy's Board of Directors effective July 29, 2026, and appointed to the Audit Committee and Governance, Compensation and Nominating Committee. The filing explicitly states the Board determined Mr. Carter is independent and meets Nasdaq independence requirements. This is a clear director appointment under Item 5.02(d), and the addition of an experienced executive from a major corporation to the board is material to investors assessing governance quality and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
Shailesh Jejurikar has been appointed as Chairman of the Board effective August 1, 2026, in addition to his existing role as President and CEO, representing a significant governance change at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
V.F. Corporation appointed Abhishek Dalmia as Executive Vice President and Chief Financial Officer effective August 1, 2026, with expanded responsibilities to also serve as Chief Operating Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-29
Item 5.02
Andreas W. Mattes was appointed as a director and chair of the Compensation Committee effective July 28, 2026. The appointment brings significant semiconductor industry experience, including prior CEO roles at Coherent and Diebold Nixdorf, and includes compensation terms of an $80,000 annual retainer plus a $500,000 initial RSU grant.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
Jack Henris was appointed as Chief Executive Officer and Director of Dakota Gold Corp., effective August 18, 2026, with compensation terms including a $360,000 base salary, 75% discretionary bonus, and $630,000 long-term incentive compensation. This appointment represents a significant leadership transition at the development-stage mining company as it prepares for the Richmond Hill Gold Project development phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Keith Schwarz was appointed as an independent director and audit committee member effective July 29, 2026, with compensation including an annual cash retainer of $100,000, audit committee retainer of $15,000, and a $150,000 equity grant.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
The press release announces the appointment of Depesh Narotam as an independent director of XORTX Therapeutics Inc., effective July 27, 2026. He has also been appointed to the Compensation, Governance and Nominating Committee. This is a clear executive/board appointment disclosure, material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-29
Item 5.02
The filing discloses the appointment of two new directors, Sharon L. O'Keefe and Thomas A. West, to the Board effective July 28, 2026, following an increase in authorized board size from seven to nine directors. While the section also mentions reclassifications of existing directors Burke and Taylor for rebalancing purposes, the principal disclosed action centers on the election of two new directors with specified committee assignments and compensation arrangements. This is material as it represents a change in board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The Board appointed Kimberly Hawley as Interim Chief Financial Officer effective July 6, 2026, with an employment agreement providing $250,000 annual base salary and a $50,000 restricted stock grant. While the disclosure includes compensatory details, the principal disclosed action is the appointment of a named executive to a C-suite officer role, making this an executive appointment event. The appointment of an interim CFO is material to investors assessing the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Jeffrey Harris was appointed to the Board of Directors as a Class II director effective July 26, 2026, filling a vacancy. While Harris previously served as CEO and founder of SpringBig before his resignation on March 31, 2025, the principal disclosed action here is his appointment to the Board. This is a material governance event involving a significant figure in the company's history returning to a leadership position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Three directors—Melvin D. Lindsey, Richard W. Cook, and Christopher Heatherly—were appointed to the Board effective July 27, 2026, in connection with the IPO, with assignments to the Audit, Compensation, and Corporate Governance and Nominating committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
The press release announces the re-appointment of Marco Leone to Nuvini's Board of Directors as an independent director, effective July 27, 2026. The appointment is material because it directly addresses a Nasdaq compliance issue: the Company had fallen out of compliance with Nasdaq Listing Rule 5605 (requiring a minimum of three independent directors on the audit committee), and Leone's election as an independent director restored that compliance. This is a governance event with direct regulatory and operational significance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
EX-99.1
Marcelo Ken Suhara was appointed on July 27, 2026, as Chair Member of Afya's Audit, Risks and Ethics Committee, succeeding João Paulo Seibel de Faria who passed away. This is a material governance appointment to a key committee leadership role overseeing audit and risk matters, affecting the composition and leadership of the company's audit oversight function.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-29
Item 5.02
Sonos appointed Chris Shackelton as a Class II director effective July 28, 2026, increasing the board size from ten to eleven members. Shackelton is described as a long-term investor with significant experience in strategy, financial markets, and capital allocation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Alp E. Can was appointed Chief Operating Officer of the Federal Home Loan Bank of Atlanta, effective August 10, 2026, representing a material promotion to a senior C-suite position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
The filing announces the appointment of Jonathan M. Collins as Executive Vice President and Chief Financial Officer effective August 10, 2026, along with the concurrent appointment of Todd W. Fister as President and Chief Operating Officer. While the disclosure includes compensatory details (base salary of $775,000, equity awards totaling $4.5 million, and a $500,000 sign-on bonus), the principal disclosed action is the appointment of these executives to new roles. The filing also mentions retention awards to other named executive officers, but these are secondary to the primary executive appointments. This is material as it involves changes to senior leadership positions critical to the company's operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-29
Item 5.02
The Company appointed three executives and directors effective July 31, 2026: Zoran Milošević as Chief Executive Officer, William Scott as Chief Financial Officer (transitioning from Interim CEO while remaining Chairman), and Michael Prescott as an Independent Director, as part of a Board-led succession process to drive the next stage of global expansion.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-07-29
EX-99.1
The exhibit announces the appointment of David Sturgeon as Chief Financial Officer of RedCloud Holdings plc, effective August 1, 2026. This is a clear executive appointment of a named officer to a C-suite role at a recently-listed public company. The disclosure emphasizes his extensive experience at Nasdaq-listed companies and his expertise in SEC reporting, investor relations, and corporate governance — all material to a recently-listed, high-growth company's governance and financial leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-29
Item 5.02
Sheila Gujrathi, M.D., was appointed to Processa's Board of Directors effective immediately after the merger closing on July 28, 2026, bringing extensive biopharmaceutical industry experience as part of the leadership changes resulting from the Vidya acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Doug Stiles was appointed President of Silver Bow Mining Corp. effective July 27, 2026, having previously served as Vice President of Regulatory and External Affairs since February 2026. The appointment is material given his 25+ years of mining experience and critical role in advancing the company's flagship Rainbow Block Project.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
David Smith, a current director, was appointed to serve as Interim Chief Financial Officer effective July 27, 2026, following the placement of recently appointed CFO Jason Knoblauch on paid leave due to pending litigation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-29
Item 5.02
The filing discloses both a director departure (David Barse's resignation on July 27, 2026) and a director appointment (Daniel Lewis elected to the Board on July 27, 2026, effective immediately). While both events are disclosed, the substantive focus and forward-looking impact center on the appointment of Lewis as a new director with a term through the 2027 annual meeting. The departure is explicitly stated as non-contentious and unrelated to disagreements. The appointment is the material governance action that affects board composition going forward.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-29
The filing announces the appointment of Olaf Koch as Non-Executive Director of Vodafone Group Plc effective 27 July 2026, following shareholder approval at the 2026 Annual General Meeting. Koch will also join the Remuneration Committee and ESG Committee effective 1 August 2026. This is a clear executive appointment disclosure under the governance domain, material to investors as it affects board composition and committee membership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
James S. Filter, the Company's President and Chief Executive Officer, was appointed as a director of Schneider National, Inc. effective July 27, 2026. The Board increased its size from ten to eleven directors to accommodate this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-07-29
Item 5.02
Michael Easton was appointed Executive Vice President & Chief Financial Officer effective August 8, 2026, succeeding Jonathan Collins. Easton was promoted internally from Senior Vice President and Chief Accounting Officer, bringing 25+ years of financial expertise. Matthew Lisowski was simultaneously appointed Senior Vice President, Chief Accounting Officer, also effective August 8, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Chandu Thota was appointed as a Class II director of Dynatrace effective July 27, 2026, increasing the Board size from 10 to 11 directors. Thota brings 20+ years of experience in AI, cloud infrastructure, and enterprise software from leadership roles at Google and Microsoft, and is determined to be independent by the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-29
Item 5.02
Core Scientific appointed Mark W. Adams to its Board of Directors, effective July 29, 2026. Adams brings over 25 years of technology sector experience, including prior roles as President and CEO of Penguin Solutions and President of Micron Technology, and meets independence requirements under Sarbanes-Oxley and Nasdaq listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-28
Item 5.02
The Board appointed John F. Ghingo as President and Chief Executive Officer effective October 26, 2026, representing a material promotion from his current role as President. While the disclosure also includes compensatory arrangements (salary increase to $1.28 million, long-term incentive target of $6.8 million, and severance provisions), the principal disclosed action is Ghingo's appointment to the CEO role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses the appointment of Ms. Kristen J. Pederson as a new director to NPK International's Board, effective July 28, 2026, with concurrent appointment to the Audit, Compensation, and Nominating and Corporate Governance Committees. The principal disclosed action is a person taking a role (director and committee member), making this an exec_appointment. The disclosure includes her extensive background in corporate governance, board experience, and compensation details (pro-rated cash and equity retainers), which are material to investors assessing board composition and governance strength.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-28
Item 5.02
Martin Madaus was elected as a director of Haemonetics Corporation, effective July 24, 2026, and appointed to the Audit Committee and Governance and Compliance Committee.
View raw filing on EDGAR →